Company Overview
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Recent Developments
- Dec 2025 Revenue of $17.44M (+16.0% YoY); net profit $-21.23M.
- Trailing 12 Months Year-on-year growth — revenue +34.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.89% |
| 1 Year: | 34.90% |
Stock Price Performance
| 1 Year: | -96.10% |
| 6 Months: | -86.49% |
| 3 Months: | -79.34% |
| 1 Month: | -44.54% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)28.27 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 96.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VVOS Vivos Therapeutics, Inc. PHARMA | 0.18 | -0.10 | $3.62M | 0.00% | - | - | 8.89% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.20M | 3.27M | 3.29M | 3.45M | 4.50M | 4.55M | 3.64M | 4.18M | 4.25M | 3.86M | 3.40M | 3.30M | 3.42M | 4.05M | 3.86M | 3.02M | 3.82M | 6.78M | 3.82M | 5.14M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51M | 1.71M | 2.85M | 836.00K | 2.08M |
| Gross Profit | 2.42M | 2.73M | 2.58M | 2.69M | 3.62M | 3.18M | 2.55M | 2.59M | 2.50M | 2.34M | 2.10M | 1.75M | 1.94M | 2.65M | 2.33M | 1.51M | 2.11M | 3.94M | 2.99M | 3.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.43M | 6.97M | 8.67M | 9.37M | 9.67M |
| Operating Income | -2.56M | -1.42M | -1.82M | -3.41M | -4.06M | -5.50M | -6.64M | -6.96M | -5.41M | -5.00M | -4.52M | -3.64M | -3.79M | -1.94M | -2.65M | -3.92M | -4.87M | -4.73M | -6.38M | -6.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.74M | -4.56M | -4.35M | -5.94M | -6.16M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.86M | -5.01M | -5.40M | -6.95M | -7.75M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.58M | -1.41M | -1.81M | -3.40M | -4.04M | -5.45M | -5.33M | -6.99M | -5.43M | -1.70M | -5.53M | -2.09M | -3.76M | -1.93M | -2.62M | -3.86M | -5.01M | -5.40M | -6.95M | -7.68M |
| Diluted EPS | - | - | - | - | - | - | -0.25 | -0.33 | -6.40 | -1.72 | -4.62 | -1.75 | -1.63 | -0.60 | -0.40 | -0.45 | -0.55 | -0.49 | - | -0.52 |
| R&D Expense | - | - | - | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.39M | 13.07M | - | 16.02M | 13.80M | 15.03M | 17.44M |
| Cost of Revenue | - | - | - | 6.00M | 5.53M | 6.01M | 6.90M |
| Gross Profit | 8.66M | 10.41M | - | 10.02M | 8.27M | 9.02M | 10.54M |
| Operating Expenses | - | - | - | 35.05M | 25.57M | 20.19M | 30.44M |
| Operating Income | -10.58M | -12.04M | - | -25.03M | -17.30M | -11.17M | -19.89M |
| EBITDA | - | - | - | -24.36M | -16.68M | -10.59M | -18.59M |
| Interest Expense | - | - | 14.00K | 0 | - | - | - |
| Pretax Income | - | - | - | -23.84M | -13.58M | -11.14M | -21.23M |
| Tax Provision | - | - | 0 | 0 | - | - | - |
| Net Income | -10.75M | -12.06M | - | -23.84M | -13.58M | -11.14M | -21.23M |
| Diluted EPS | - | - | - | -25.90 | -11.14 | -2.22 | -2.07 |
| R&D Expense | - | - | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.55M | 25.33M | - | 13.72M | 10.73M | 15.28M | 25.15M |
| Current Assets | - | - | - | - | 5.42M | 2.46M | 7.47M | 4.38M |
| Cash & Equivalents | - | 469.35K | 18.21M | - | 3.52M | 1.64M | 6.26M | 2.03M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 457.00K | 202.00K | 430.00K | 1.58M |
| Total Liabilities | - | 9.18M | 8.41M | - | 8.92M | 10.32M | 7.33M | 26.70M |
| Current Liabilities | - | 9.09M | 7.84M | - | 6.81M | 7.29M | 4.98M | 18.08M |
| Long Term Debt | - | 3.71M | 423.00K | - | - | - | - | 469.00K |
| Total Debt | - | - | - | - | 2.41M | 2.00M | 1.51M | 13.50M |
| Total Equity | 4.83M | -2.94M | 16.92M | - | 4.80M | 411.00K | 7.95M | -1.49M |
| Shares Outstanding | - | - | - | - | 920.48K | 1.83M | 5.89M | 9.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.34M | -5.68M | - | -19.59M | -11.95M | -12.69M | -15.26M |
| Investing Cash Flow | 86.22K | -120.00K | - | -924.00K | -853.00K | -568.00K | -7.53M |
| Financing Cash Flow | 4.47M | 23.54M | - | 0 | 10.92M | 17.88M | 18.56M |
| Capital Expenditure | -175.60K | -120.00K | - | -924.00K | -803.00K | -568.00K | -2.34M |
| Free Cash Flow | -5.52M | -5.80M | - | -20.51M | -12.75M | -13.26M | -17.60M |
| Net Change in Cash | - | - | - | -20.51M | -1.88M | 4.62M | -4.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 76.0% | 79.7% | - | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating Margin % | -92.8% | -92.1% | - | -156.2% | -125.3% | -74.3% | -114.1% |
| Net Margin % | -94.4% | -92.3% | - | -148.8% | -98.4% | -74.1% | -121.7% |
| ROE % | 365.4% | -71.3% | - | -496.7% | -3,304.9% | -140.0% | 1,424.8% |
| ROCE % | 685.9% | -68.9% | - | -362.4% | -502.6% | -108.4% | -281.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Geode Capital Management, LLC | 0.61% | 85.00K | $13.87K |
| 2 | IHT Wealth Management, LLC | 0.55% | 76.74K | $12.52K |
| 3 | Vanguard Capital Management LLC | 0.44% | 60.63K | $9.89K |
| 4 | Commonwealth Equity Services, LLC | 0.31% | 42.50K | $6.94K |
| 5 | UBS Group AG | 0.28% | 39.15K | $6.39K |
| 6 | B. Riley Wealth Advisors, Inc. | 0.27% | 38.07K | $6.21K |
| 7 | Centurion Wealth Management LLC | 0.26% | 35.68K | $5.82K |
| 8 | Blackrock Inc. | 0.20% | 27.82K | $4.54K |
| 9 | State Street Corporation | 0.18% | 24.92K | $4.07K |
| 10 | Sequoia Financial Advisors, LLC | 0.17% | 24.00K | $3.92K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VVOS
Vivos Therapeutics Announces Material Debt Reduction
Company Continues to Make Significant Progress to Enhance Stockholders' Equity and Satisfy Nasdaq Listing RequirementsLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a…
Vivos Therapeutics to Present at the 2026 Moody Capital Solutions Disruptive Growth & Life Sciences Conference
Littleton, Colorado--(Newsfile Corp. - September 1, 2026) - Vivos Therapeutics, Inc. (NASDAQ: VVOS) ("Vivos" or the "Company"), a leading medical technology and healthcare services company focused on the diagnosis and treatment of obstructi…
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
Physician-Aligned Collaboration to Support a Regional Sleep & Airway Medicine Center in Palm Beach CountyLITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (Nasdaq: VVOS), a leading medic…
Vivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
Average Weekly New Patient Referrals into Vivos’ Nevada Sleep & Airway Medicine Centers Rose 212% Over the Past Six Weeks from the Prior Six WeeksLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or “the …
Vivos Therapeutics shares slide after Q2 revenue falls short of forecasts
Vivos Therapeutics Inc. (NASDAQ:VVOS) shares fell 6.
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
Vivos Therapeutics (VVOS) delivered earnings and revenue surprises of +26.19% and -5.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
VVOS — Frequently Asked Questions
What is the current share price of Vivos Therapeutics, Inc. (VVOS)?
As of 2026-09-19 21:16 PDT, Vivos Therapeutics, Inc. (VVOS) trades at $0.18 on NasdaqCM. Its 52-week range is $0.17 to $4.69.
What is the market capitalisation of VVOS?
Vivos Therapeutics, Inc. (VVOS) has a market capitalisation of $3.62M on NasdaqCM.
What is the P/E ratio of VVOS?
VVOS trades at a trailing price-to-earnings (P/E) ratio of -0.10. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.48.
Is VVOS a good stock to buy?
This page provides a data-driven analysis of Vivos Therapeutics, Inc. (VVOS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.